Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patiromer in pediatric hyperkalemia (EMERALD)
NCT03087058Phase 2Terminated
- Sponsor
- Vifor Pharma
- Start
- Jul 2017
- Primary completion
- Jan 2021
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of patiromer in hyperkalemia, sponsored by Vifor Pharma. Started Jul 2017; status: terminated.
02
Drugs
patiromer
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT03087058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03087058.